Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference

Rhea-AI Summary

Ensysce Biosciences announced participation in the H.C. Wainwright BIOCONNECT Conference from January 10-13, 2022. CEO Lynn Kirkpatrick and CFO Dave Humphrey will engage in one-on-one meetings with investors. An on-demand presentation will be available on the company’s Investor Relations website starting January 10, 2022, at 7:00 am ET. Ensysce focuses on developing safer prescription drugs utilizing innovative technology platforms aimed at combating opioid abuse and overdose mortality.

Positive

• Participation in a prominent investor conference.
• Management availability for one-on-one investor meetings.
• Innovative drug development aimed at opioid abuse prevention.

Negative

• None.

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today announced management’s participation in the H.C. Wainwright BIOCONNECT Conference being held virtually January 10-13, 2022.

An on-demand presentation from the H.C. Wainwright conference will be available through Ensysce’s Investor Relations website at https://ir.ensysce.com/ beginning January 10, 2022, at 7:00am ET.

The Company’s Chief Executive Officer Lynn Kirkpatrick, PhD and Chief Financial Officer Dave Humphrey will be available for one-on-one and small group meetings with investors. To schedule a meeting with Ensysce management, please contact your conference representative or you may also email your request to ENSC@mzgroup.us.

About Ensysce Biosciences

Ensysce Biosciences, San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.

Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us

Source: Ensysce Biosciences Inc.

FAQ

What is the date of the H.C. Wainwright BIOCONNECT Conference for Ensysce Biosciences?

The H.C. Wainwright BIOCONNECT Conference will take place from January 10-13, 2022.

Where can I find the on-demand presentation from Ensysce Biosciences?

The on-demand presentation will be available on Ensysce’s Investor Relations website starting January 10, 2022, at 7:00 am ET.

Who will represent Ensysce Biosciences at the conference?

CEO Lynn Kirkpatrick and CFO Dave Humphrey will represent Ensysce Biosciences at the conference.

How does Ensysce Biosciences aim to address opioid abuse?

Ensysce focuses on developing tamper-proof opioids using their proprietary technology platforms.

What are the stock symbols for Ensysce Biosciences?

Ensysce Biosciences is traded under the stock symbols ENSC and ENSCW.